Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” studyNarendranath Epperla, Timothy S. Fenske, Oscar Calzada et al.|Hematological Oncology|2017Cited by 68
De novo <scp>CD</scp>5+ diffuse large <scp>B</scp>‐cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohortLapo Alinari, Kristie A. Blum, Alejandro A. Gru et al.|American Journal of Hematology|2016Cited by 49
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL).Narendranath Epperla, Timothy S. Fenske, Mehdi Hamadani et al.|Journal of Clinical Oncology|2016Cited by 0